CFH and age-related macular degeneration: Supplementary Figures S284 to S306 show box plots of the complement-associated protein intensities at baseline, Month 1, and Month 2, stratified on GRS (1–2, 2–3, >3), CFH Y402H variant (non-risk, heterozygous, homozygous), C3 R102G variant (non-risk, heterozygous, homozygous), age, sex, and AMD status. No striking trends in treatment response were observed between genetic risk profiles, although values prior to treatment sometimes appeared higher (C3 in Supplementary Fig. S291) or lower (CFH in Supplementary Fig. S303) in carriers of risk variants.